Search Results for keywords:"Regulatory Freeze Pending Review"

The Department of Veterans Affairs (VA) has temporarily delayed the effective date of their rule on Prosthetic and Rehabilitative Items and Services originally set for January 27, 2021. The rule will now take effect on February 26, 2021, to allow VA officials additional time to review the regulations, following a directive from the Presidential memorandum issued on January 20, 2021, calling for a regulatory freeze pending review. This action, which includes no public comment period, is based on the good cause exception to provide time for the new administration to evaluate the policy implications of the rule without delaying the delivery of services unnecessarily.

The Department of Health and Human Services (HHS) published a final rule concerning a new Privacy Act system of records called "NIH Police Records" maintained by the National Institutes of Health (NIH). Originally scheduled to take effect on February 18, 2025, this rule's start date is now delayed until March 21, 2025. The delay follows a memorandum from President Trump titled "Regulatory Freeze Pending Review," which suggested postponing the implementation of such rules for 60 days to allow for further review. The shift aims to ensure a comprehensive consideration of the rule's impact.

The Federal Transit Administration (FTA) has announced that it will not enforce the regulations of the State Safety Oversight final rule, which was published on October 18, 2024, until March 20, 2025. This decision aligns with the President's memorandum titled “Regulatory Freeze Pending Review,” which suggests delaying rules to ensure they align with current laws and policies. The rule aims to implement new safety requirements from the Infrastructure Investment and Jobs Act and streamline notification processes. This pause allows time for a thorough review to confirm their compliance with legal and administrative principles.

The National Highway Traffic Safety Administration (NHTSA) announced a delay in the effective date of a new rule regarding seat belt warning systems. Initially set to take effect on January 3, 2025, this rule requires a seat belt use warning for rear seats and updates the warning standards for front seats. The delay, pushing the effective date to March 20, 2025, is due to a regulatory review mandated by the President's memorandum. This decision is enacted immediately and is exempt from notice and comment procedures.

The Department of Health and Human Services (HHS) has delayed the effective date of a final rule concerning updates to the Health Insurance Portability and Accountability Act (HIPAA) standards for retail pharmacy transactions and Medicaid pharmacy subrogation until April 14, 2025. This delay, following a Presidential memorandum on regulatory review, allows HHS more time to consider the new regulations. The compliance date for these standards is also extended to April 14, 2028. The immediate implementation of this delay is based on good cause exceptions, as it is impractical to seek public comment given the circumstances.

The Agricultural Marketing Service of the USDA has delayed the effective date of a rule regarding plant records for the Dairy Grading and Inspection Program. Originally set for January 16, 2025, the rule's new effective date is March 21, 2025. This rule allows butterfat tests to be conducted at either in-house or third-party labs and requires records to be available for USDA inspector review. The delay is part of a regulatory review to ensure compliance with a recent presidential memorandum.

The National Highway Traffic Safety Administration (NHTSA) has announced a delay in the effective date of a rule aimed at improving child restraint and anchorage systems in vehicles. Originally scheduled to take effect on January 7, 2025, the rule will now be effective on March 20, 2025. This delay is in response to a memorandum from the President ordering a review of new regulations. The delay allows further evaluation before the rule is implemented and will help ensure it aligns with public interest and governmental guidelines.

In response to a memorandum from President Donald J. Trump, the National Marine Fisheries Service (NMFS) has delayed the effective date of the 2025 Atlantic deep-sea red crab fishing specifications. Originally set to take effect on February 27, 2025, the specifications will now be implemented on March 31, 2025, to allow for further review. Until the new specifications take effect, the 2024 specifications will remain in place to govern the fishery. This delay is part of a broader temporary postponement of rules yet to take effect, giving agencies time to review any factual, legal, or policy questions.

The Federal Motor Carrier Safety Administration (FMCSA) of the U.S. Department of Transportation issued a final rule delaying the effective date of its "Rulemaking Procedures Update" to March 21, 2021. This decision follows a memorandum from January 20, 2021, by the Assistant to the President and Chief of Staff, to give time for the President's appointees or designees to review the rule. The delay aims to ensure thorough consideration of any questions concerning facts, law, or policy before the rule becomes effective. Normally, agencies have to provide notice and allow comments before implementing rules, but this requirement is waived if deemed impracticable or against public interest.

The Food and Drug Administration (FDA), under the Department of Health and Human Services, has delayed the effective date of a rule regarding nonprescription drug products with an additional condition for nonprescription use (ACNU). Originally set to take effect on January 27, 2025, the rule is postponed to March 21, 2025, due to a memorandum from the President calling for a "Regulatory Freeze Pending Review." This delay is intended to allow further examination of the rule and its implications, ensuring it aligns with legal and policy considerations. The rule outlines requirements for nonprescription drugs involving applications, labeling, and postmarketing reporting, differentiating them from prescription drugs based on these additional conditions.